SEC EDGARAUG 241 min read$PODD

McEvoy Ashley purchased $162K of PODD

McEvoy Ashley (President and CEO) purchased 1,100 shares of INSULET CORP (PODD) at $147.47 ($0.16M total) on 2026-08-21.

Original reporting

SEC EDGAR · McEvoy Ashley

Published Aug 24, 2026, 11:08 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Aug 24, 2026, 11:13 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$PODD

Neutral

medium confidence

Mentioned

$PODD

Relevance

5/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$PODDNeutralLow

Why it matters

The purchase modestly raises insider ownership, offering a slight confidence cue but unlikely to move the stock significantly.

Market read

A small insider buy provides a minor bullish hint for PODD but limited trading relevance.

What to watch

Potential upcoming product launches or regulatory news not disclosed in the filing.

Relevance 5/10Novelty 4/10Timing: filing date 2026-08-24

Background

Form 4 filings disclose insider trades; investors watch for material changes in insider holdings.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$PODDNeutralMedium confidence

Context

President and CEO Ashley McEvoy bought 1,100 shares for $162,217, increasing his stake to 23,731 shares.

Expected impact

Minor upward pressure, likely limited to short-term sentiment.

Evidence & confidence

Form 4 is primary source; purchase amount is under $1M for a mid‑cap, so impact is small.

Market effects

Sector

Insulet operates in medical devices; insider buying may be noted by sector analysts but no broader effect.

Regional

US market only; no regional ripple.

Global

Limited to investors tracking Insulet.

Counterpoint

What could challenge this read

Insider purchase could be a routine portfolio rebalancing, not a strong bullish signal.

Key entities

Company
Insulet Corp
Medical device maker listed as PODD.
Executive
Ashley McEvoy
President and CEO of Insulet.

Read at source ← All news

SEP 14

$RMDMedAI 8/10

Patient Monitoring Stocks Q2 Teardown: ResMed (NYSE:RMD) Vs The Rest

ResMed (RMD) and peers reported Q2 earnings, with revenues beating estimates by 1.4% but next quarter's guidance below. RMD's revenue grew 8.6% YoY, meeting expectations, while iRhythm (IRTC) saw 20.1% growth, exceeding estimates. Insulet (PODD) and DexCom (DXCM) also reported, with mixed results. Stocks have declined since earnings, with RMD down 2.3% and IRTC down 13%.

yahoo.com3 min

SEP 8

$PODDMed

Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?

Insulet PODD reports strong growth in Omnipod 5 AID system adoption, with Q2 2026 revenues up 23.8%. The company faces competition and macroeconomic pressures but has raised international growth guidance. PODD's earnings beat estimates for four straight quarters, with a 22.2% long-term growth rate. Management expects continued expansion and product development, including Omnipod 6 and a Type 2 system launch in 2027.

tradingview.com3 min

SEP 4

$PODDMedAI 8/10

Unpacking Q2 Earnings: Insulet (NASDAQ:PODD) In The Context Of Other Patient Monitoring Stocks

Insulet (PODD) reported Q2 revenue of $801.7M, up 23.5% YoY, beating estimates by 1.9% but missing next quarter's guidance. Peers iRhythm (IRTC), ResMed (RMD), and DexCom (DXCM) also reported earnings, with mixed market reactions. PODD is down 11.6% since reporting, while DXCM is up 20.6%.

finance.yahoo.com3 min

SEP 3

$IRTCMed

Q2 Earnings Highs And Lows: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks

iRhythm (IRTC) reported Q2 revenue of $224.2M, up 20.1% YoY, beating estimates. ResMed (RMD) reported $1.46B in revenue, up 8.6% YoY, in line with expectations. Insulet (PODD) reported $801.7M in revenue, up 23.5% YoY, beating estimates but missing guidance. IRTC stock is down 4.4%, RMD up 3.4%, and PODD down 11.6% since reporting.

finance.yahoo.com2 min

AUG 30

$PODDMed

Is Class Action Scrutiny Of Omnipod Controls Altering The Investment Case For Insulet (PODD)?

Insulet (PODD) faces class action lawsuits alleging false statements about manufacturing controls and safety risks in its insulin delivery products. The lawsuits, filed by Robbins Geller and Rosen Law Firm, cover shares bought between February 2025 and May 2026. Insulet maintains revenue growth guidance of 21-23% for 2026 despite recent recalls affecting 7 million units. Analysts project varying revenue and earnings estimates for 2029, with growth potential but increased risks due to manufacturi

simplywall.st3 min

AUG 12